EB (Ethyl Butyrate) as a Cosolvent of Electrolyte Tuning an Ultrathin CEI Membrane for Improving the Ultralow-Temperature Behaviors of LiNi_0.8Co_0.1Mn<sub>0.1<... by Lucheng Li (13753395)

Subjects:

EB (Ethyl Butyrate) as a Cosolvent of Electrolyte Tuning an Ultrathin CEI Membrane for Improving the Ultralow-Temperature Behaviors of LiNi_0.8Co_0.1Mn<sub>0.1<... by Lucheng Li (13753395)

Subjects:

Expression of AC5 and AC6 in WT and AMPKα2-/- mice. by Anne Garnier (130125)

Subjects:

SEM images of the samples (a) virgin sample (b) 0.4 wt. % <i>f-MWCNTs</i> (c) 0.5 wt. % <i>f—MWCNTs</i>. by Shaban Gul (14309526)

Subjects:

Changes in 50-kHz USV duration (A-D) and amplitude (E-H) in rats with 7 (ABEF) or 14 (CDGH) training days during training (ACEG) and test (BDFH) sessions. by Agnieszka D. Wardak (17941139)

Neuronal expression of A53T, E46K, G51D, and H50Q αSyn showed an early decline in locomotor function. by Ryusuke Sakai (2961507)

“…Flies expressing either A53T, E46K, G51D, or H50Q αSyn showed a significant decrease in locomotor function compared with control flies, whereas flies expressing WT αSyn did not. …”

Olaparib reverses the oxLDL-mediated decrease in co-immunoprecipitation of IκBα with RelA or p50. by Khamis Mustafa (17941332)

“…Relative band densities from three independent experiments were analyzed. (A) OxLDL decreased co-immunoprecipitation of IκBα with both RelA and p50, and olaparib reversed the effect of oxLDL on the dissociation of IκBα with RelA and p50. …”

Heat map showing time dependent changes for all genes with a ≥ 2-fold maximal increase or decrease in gene expression (mRNA) in response to single doses of IFN-γ. by Daniel R. Ambruso (12042605)

ALK^wt–ABT199 interactions. by Richard Junior Zapata Dongo (17912565)

Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…<p>In the recurrence group, mean outpatient visits (± standard deviation) decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

GC-MS chromatogram of garlic essential oil. by Huda H. Elbehery (22492996)

“…GO-GA NPs enhanced the persistence activity, exhibiting a continued toxic effect for >30 days, with a PT₅₀ of 22.29 days compared to 12.79 days for GO. …”

Colon tissue and organoid AJC protein expression is decreased with LD shifting in Per2::Luc mice. by Laura Tran (10924702)

“…<p><b>(A)</b> Immunofluorescent staining of E-cadherin (red) in the colon tissue and organoids of shifted and non-shifted Per2::Luc mice. …”

Spatial exploration patterns of non-tumor bearing mice under different treatment conditions in the Morris Water Maze (MWM). by Robert Botelho (20308297)

SARS-CoV-2 inhibits SG formation and decreases expression of G3BP1. by Stacia M. Dolliver (13822801)

The expression of <i>Wnt1</i> gene was decreased in <i>Bmpr</i> double knockout mutants. by Lihua Qin (494786)

Elevated IDO activity in HD mouse brains is decreased by <i>ex-vivo</i> iron chelation. by David W. Donley (3111198)

“…<p>Mouse pups were supplemented with carbonyl iron from postnatal days 10–17 and then were sacrificed at 14 weeks of age. <b>A.</b> Striatal IDO activity is increased in N171-82Q HD mice and significantly decreased by <i>ex vivo</i> iron (III) chelation (50 μM deferoxamine). …”

Five genes involved in piRNA biosynthesis were commonly down-regulated in the two <i>enok</i> mutants as compared with the WT control, while the expression levels of <i>piwi</i>, <i>AGO3</i> and <i>aub</i> were not decreased in <i>enok</i> mutants. by Shih-Ying Tsai (3576587)

Comparison of the histopathological changes after KA/E2 treatment in WT and TLR2 KO mice. by Mi-Kyung Park (56053)

Lipopolysaccharide (LPS) treatment decreases the density of neurons in the ischemic cortical region after stroke in a microglia-dependent manner. by Eric Yuhsiang Wang (17131666)

Subjects:

Proline catabolism is required for virulence in <i>Drosophila</i> and murine infection models. by Fitz Gerald S. Silao (9384713)